Currently, there are 4 indications on parallel tracks. Once one is approved the others won't be far behind. The idea that as one drug finishes testing and enters the market the next begins trials is preposterous. No company with multiple drugs does that.
Drugs such as flucide and hivcide will take longer than topical indications. Flucide will need a large body of clinical evidence as a broad spectrum treatment against all forms of flu. Hivcide may require extensive blood work and longterm monitoring of subjects at each phase. Eye and genital herpes as two different drugs each only have to show a shorter time for clearing of infection or eruptions than non treatment. Denguecide will be similar to a topical in that it either works to speed recovery or it doesn't. The single issue that will slow trials will be close monitoring for counter indications and side effects as an injectable.
I stand by my statement. Once the first indication is approved for market, the next two will be less than a year away.
News 
Market Data 
Discover 
